Department of Urology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Department of General Surgery, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, PR China.
Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166968. doi: 10.1016/j.bbadis.2023.166968. Epub 2023 Nov 24.
Revealing the possible molecular mechanism of the NR4A1 (nuclear receptor subfamily 4 group A member 1)-MDM2 (MDM2 proto-oncogene)-P53 (tumor protein p53) signaling pathway that induces ferroptosis in renal tubular epithelial cells. Renal ischemia-reperfusion injury (RIRI) -related datasets were obtained from the GEO database. Differentially expressed genes in RIRI were analyzed using R language, intersected with RIRI-related genes in the GeneCard database, and retrieved from the literature to finally obtain differential ferroptosis-related genes. An in vitro cell model of RIRI was constructed using mouse renal cortical proximal tubule epithelial cells (mRTEC cells) treated with hypoxia-reoxygenation (H/R). Bioinformatic analysis showed that NR4A1 may be involved in RIRI through the induction of ferroptosis; in addition, we predicted through online databases that the downstream target gene of NR4A1, MDM2, could be targeted and regulated by ChIP and dual luciferase assays, and that NR4A1 could prevent MDM2 by inhibiting it, and NR4A1 was able to promote ferroptosis by inhibiting the ubiquitinated degradation of P53. NR4A1 expression was significantly increased in mRTEC cells in the hypoxia/reoxygenation model, and the expression of ferroptosis-related genes was increased in vitro experiments. NR4A1 reduces the ubiquitinated degradation of P53 by targeting the inhibition of MDM2 expression, thereby inducing ferroptosis and ultimately exacerbating RIRI by affecting the oxidative respiration process in mitochondria and producing oxidized lipids. This study presents a novel therapeutic approach for the clinical treatment of renal ischemia-reperfusion injury by developing drugs that inhibit NR4A1 to alleviate kidney damage caused by renal ischemia-reperfusion.
揭示 NR4A1(核受体亚家族 4 组 A 成员 1)-MDM2(MDM2 原癌基因)-P53(肿瘤蛋白 p53)信号通路诱导肾小管上皮细胞发生铁死亡的可能分子机制。从 GEO 数据库中获取与肾缺血再灌注损伤(RIRI)相关的数据集。使用 R 语言分析 RIRI 中的差异表达基因,与 GeneCard 数据库中的 RIRI 相关基因进行交集,并从文献中检索,最终获得差异表达的铁死亡相关基因。使用缺氧-复氧(H/R)处理的小鼠肾皮质近曲小管上皮细胞(mRTEC 细胞)构建 RIRI 的体外细胞模型。生物信息学分析表明,NR4A1 可能通过诱导铁死亡参与 RIRI;此外,我们通过在线数据库预测,NR4A1 的下游靶基因 MDM2 可以被 ChIP 和双荧光素酶测定靶向和调节,NR4A1 可以通过抑制 MDM2 来防止 MDM2,NR4A1 可以通过抑制 P53 的泛素化降解来促进铁死亡。在缺氧/复氧模型中,mRTEC 细胞中 NR4A1 的表达明显增加,体外实验中铁死亡相关基因的表达增加。NR4A1 通过靶向抑制 MDM2 表达减少 P53 的泛素化降解,从而诱导铁死亡,并最终通过影响线粒体氧化呼吸过程和产生氧化脂质来加重 RIRI。本研究通过开发抑制 NR4A1 的药物为肾缺血再灌注损伤的临床治疗提供了一种新的治疗方法,从而减轻肾缺血再灌注引起的肾脏损伤。